

www.elsevier.com/locate/euroneuro

Glutamate-Mediated Excitotoxicity in Schizophrenia: A Review

Eric Plitman, Shinichiro Nakajima, Camilo de la Fuente-Sandoval, Philip Gerretsen, M. Mallar Chakravarty, Jane Kobylianskii, Jun ku Chung, Fernando Caravaggio, Yusuke Iwata, Gary Remington, Ariel Graff-Guerrero

PII: S0924-977X(14)00215-6
DOI: http://dx.doi.org/10.1016/j.euroneuro.2014.07.015
Reference: NEUPSY10877

To appear in: *European Neuropsychopharmacology*

Received date: 28 May 2014
Revised date: 22 July 2014
Accepted date: 26 July 2014

Cite this article as: Eric Plitman, Shinichiro Nakajima, Camilo de la Fuente-Sandoval, Philip Gerretsen, M. Mallar Chakravarty, Jane Kobylianskii, Jun ku Chung, Fernando Caravaggio, Yusuke Iwata, Gary Remington, Ariel Graff-Guerrero, Glutamate-Mediated Excitotoxicity in Schizophrenia: A Review, *European Neuropsychopharmacology,* http://dx.doi.org/10.1016/j.euroneuro.2014.07.015

Abstract Word Count: 250
Total Word Count: 5,758

Glutamate-Mediated Excitotoxicity in Schizophrenia: A Review

Eric Plitman[a,b], Shinichiro Nakajima[a,c,d,e], Camilo de la Fuente-Sandoval[f,g], Philip Gerretsen[a,b,d,e], M. Mallar Chakravarty[e,h,i,j], Jane Kobylianskii[k], Jun ku Chung[a,b], Fernando Caravaggio[a,b], Yusuke Iwata[a,c], Gary Remington[b,e,i,l], Ariel Graff-Guerrero[a,b,d,e,i]

[a]Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
[b]Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
[c]Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
[d]Geriatric Mental Health Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
[e]Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
[f]Experimental Psychiatry Laboratory, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
[g]Neuropsychiatry Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
[h]The Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
[i]Campbell Institute Research Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
[j]Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
[k]Department of Medicine, Queen's University, Kingston, Ontario, Canada
[l]Schizophrenia Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada

Keywords: Schizophrenia, Glutamate, Glutamine, MRS, Excitotoxicity, Psychosis

Address for correspondence:
Ariel Graff-Guerrero
Centre for Addiction and Mental Health
80 Workman Way, 6th Floor
Toronto, ON M6J1H4
Canada
ariel_graff@yahoo.com.mx
416-535-8501 ext. 4834

Abstract

Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these structural alterations through an excitotoxic effect. The primary aim of this review was to describe the possible role of glutamate-mediated excitotoxicity in explaining the